Stellar Biotechnologies Appoints Two Members to SAB
News Jun 07, 2014
Stellar Biotechnologies, Inc. has announced the appointment of Gregory T. Baxter, Ph.D. and Charles V. Olson, D.Sc. to the Company's Scientific Advisory Board (SAB). They will join Daniel C. Adelman, M.D., Malcolm Gefter, Ph.D., Daniel Morse, Ph.D. and Andrew Saxon, M.D. on the SAB.
Stellar's SAB is composed of eminent scientists and physicians representing a range of disciplines including immunology, molecular biology and biochemistry. The SAB will be an ongoing resource to provide Stellar's management with counsel and guidance pertaining to the research, development, and clinical application of Stellar's KLH technology.
Dr. Gregory Baxter, a member of Stellar's Board of Directors since August 2012, is a Senior Scientist in the Department of Clinical Drug Development for CCS Associates, Inc. He also serves as Adjunct Associate Professor at Cornell University in the College of Chemical Engineering and on the Founders Board of Stanford University's StartX Med Program.
Dr. Baxter's background spans both science and business arenas including Program Director for the National Science Foundation (NSF) Division of Industrial Innovation and Partnerships; Founder and CSO of Hurel Corporation; Founder and CEO of Aegen Biosciences; and Research Scientists for Molecular Devices Corporation. Dr. Baxter received his Ph.D. in Biochemistry/Molecular Biology from the University of California, Santa Barbara.
"It's been gratifying to be a part of Stellar's corporate achievements this past year and I look forward to contributing on the Company's research front and in the advancement of its C. diff immunotherapy program," said Dr. Baxter.
Dr. Charles Olson is a biotechnology industry professional with broad scientific and operational experience, and specialization in manufacturing operations and process development. Dr. Olson currently serves as Vice President of CMC and Technical Operations for NGM Biopharmaceuticals and Vice President of Protein Sciences for Anthera Pharmaceuticals.
His background includes the positions of Senior VP of Product Development and Operations for Nexbio Inc.; VP of Hayward Operations for Cell Genesys; Senior Director of Manufacturing, Facilities and Process Development for Biomarin Pharmaceuticals; and Director of Manufacturing Sciences for Onyx Pharmaceuticals. Dr. Olson received his D.Sc. in Biochemistry from Hawthorne University.
"This is an exciting time for Stellar with its many promising commercial opportunities that the Company has in its sights," said Dr. Olson. "I am excited to join a team with such a strong technology position, and I look forward to being a part of their success."
Frank Oakes, Stellar's president and CEO, said, "We are delighted to have both of these biotechnology experts available to our internal teams and to advise our Board of Directors as we advance corporate objectives and deliver on key research and operational goals."
Human Malaria Parasites Grown for the First Time in Dormant FormNews
One of the biggest obstacles to eradicating malaria is a dormant form of the parasite which is resistant to most antimalarial drugs and can reawaken years later, causing disease relapse. Researchers have shown they can grow the dormant parasite in engineered human liver tissue for several weeks, allowing them to closely study how the parasite becomes dormant, what vulnerabilities it may have, and how it springs back to life.READ MORE
Gut Bacteria Latest Ally in Fight Against SepsisNews
Sepsis occurs when the body's response to the spread of bacteria or toxins to the bloodstream damages tissues and organs. The fight against sepsis could get a helping hand from a surprising source: gut bacteria. Researchers found that giving mice particular microbes increased blood levels of immunoglobulin A (IgA) antibodies, which protected against the kind of widespread bacterial invasion that leads to sepsis.READ MORE